Jaguar Health Reports First Quarter 2024 Financial Results
Jaguar Health (NASDAQ:JAGX) reported a 20% increase in net revenue for Q1 2024, amounting to $2.4 million compared to $2.0 million in Q1 2023, and a 4% increase from Q4 2023. The company is set to release top-line results from its Phase 3 OnTarget trial for crofelemer, aimed at treating cancer therapy-related diarrhea. A commercial launch for the FDA-approved oral mucositis product Gelclair is planned for Q3 2024. Despite a reduction in Mytesi prescription volumes, the company achieved a net loss reduction of 24%, equating to $9.2 million, compared to $12.2 million in Q1 2023. Operational loss decreased by 17%, from $9.8 million to $8.2 million, due to reductions in R&D, sales, marketing, and administrative expenses. However, the overall cost of product revenue increased slightly.
- 20% revenue increase to $2.4 million in Q1 2024 compared to Q1 2023.
- 4% revenue growth from Q4 2023 to Q1 2024.
- Net loss reduction by $2.9 million (24%) from Q1 2023 to Q1 2024.
- Operational loss decreased by $1.6 million (17%) from Q1 2023.
- R&D expenses reduced by $0.5 million.
- Sales and marketing expenses decreased by $0.5 million.
- General and administrative expenses reduced by $0.4 million.
- Mytesi prescription volumes decreased by 7% from Q4 2023 and by 2.5% from Q1 2023.
- Minimal revenues for non-prescription Neonorm products.
- Total cost of product revenue increased by $85,000.
- Net loss attributable to common shareholders remains high at $9.2 million.
- Non-GAAP recurring EBITDA shows a net loss of $7.5 million.
Insights
First-quarter 2024 financial results for Jaguar Health show a 20% year-over-year revenue increase, reaching
For retail investors, Jaguar's financial health reveals some positive trends but also areas of concern. A key metric is the decrease in loss from operations by
Non-GAAP Recurring EBITDA improved from a loss of
Top line results for the phase 3 OnTarget trial of crofelemer, aimed at treating cancer therapy-related diarrhea, are anticipated soon. This news inspires optimism, as positive outcomes could significantly impact sales and market position. Crofelemer holds potential as a important therapy for cancer patients suffering from severe side effects of treatment.
The commercial launch of Gelclair in Q3 2024 also presents a strategic expansion into cancer-related supportive care. Given that Gelclair is already FDA-approved, Jaguar can commercialize it without incurring clinical development costs, representing a cost-effective growth opportunity.
Early access to crofelemer for rare disease indications in specific EU countries further diversifies Jaguar's product portfolio and opens up additional revenue streams while bolstering its position in niche markets.
Jaguar Health's strategic moves, such as the in-license agreement for Gelclair and diversified clinical trials, illustrate a focused effort to broaden its market presence. The introduction of Gelclair in Q3 2024, without the impediment of development costs, is a notable strategic advantage.
Expanding beyond HIV-related supportive care to cancer-related supportive care aligns with current healthcare trends where targeted therapies are becoming more common. This strategic pivot could enhance Jaguar's market perception as a comprehensive provider of supportive care products, potentially attracting new investments.
Despite these positive strategic moves, Jaguar's financial performance reveals significant losses, which might deter risk-averse investors. However, for those looking at long-term growth potential, Jaguar's diversified product pipeline and strategic expansions present a promising outlook.
The combined net Q1 2024 revenue of approximately
Top line results expected to be imminent for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea
Jaguar planning to begin commercial launch in Q3 2024 for Gelclair®, the company's third prescription product
REMINDER: Jaguar to host investor webcast Tuesday, May 14th at 8:30 a.m. Eastern regarding Q1 2024 financials and company updates; Click here to register for webcast
SAN FRANCISCO, CA / ACCESSWIRE / May 14, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated first-quarter 2024 financial results and provided Company updates.
The combined net revenue for the Company's crofelemer prescription products, Mytesi® and Canalevia®-CA1, and the Company's non-prescription products was approximately
Lisa Conte, Jaguar's president and CEO, said, "Our paramount near-term clinical activity is our phase 3 pivotal OnTarget trial of crofelemer for the follow-on indication of the preventative treatment of cancer therapy-related diarrhea (CTD), an indication we also refer to as chemotherapy-induced overactive bowel (CIOB) - which includes symptoms such as unpredictable and/or chronic debilitating diarrhea and GI urgency. Top line results from this pivotal study are expected to be imminent."
As announced, Jaguar signed an exclusive 5-year in-license agreement in April 2024 for the FDA-approved oral mucositis prescription product, Gelclair, for the U.S. market. Jaguar is planning to begin the commercial launch in Q3 2024 for Gelclair.
"Gelclair is an FDA-approved prescription product and can be commercialized without any clinical development costs for Jaguar," added Conte. "We are expanding our footprint beyond HIV-related supportive care to include cancer-related supportive care, and the in-license of Gelclair is a first building block while we await the results from our pivotal Phase 3 OnTarget trial of crofelemer for CTD. We live in the age of targeted therapies, and thanks to these amazing drugs cancer patients are living longer - 5, 10, 20 years. Targeted therapies often lead to more severe side effects, however, and patients want to live, not just survive."
Jaguar, with strong leadership and participation from Jaguar family companies Napo Pharmaceuticals and Napo Therapeutics, is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure in the US, EU and Middle East/North Africa (MENA) regions, with results expected in 2024. In accordance with the guidelines of specific EU countries, published data from clinical investigations in such rare diseases could support early patient access to crofelemer for these debilitating conditions in those countries.
2024 FIRST QUARTER COMPANY FINANCIAL RESULTS:
Net Mytesi and Canalevia-CA1 Revenue: The combined net revenue for these two prescription products was approximately
Mytesi Prescription Volume: Mytesi prescription volume decreased in the first quarter of 2024 compared to the fourth quarter of 2023 by
Neonorm™: Revenues for the non-prescription Neonorm products were minimal for the first quarters of 2024 and 2023.
| Three Months Ended | ||||||||||||||||
Financial Highlights | March 31, | |||||||||||||||
(in thousands, except per share amounts) | 2024 | 2023 | $ change | % change | ||||||||||||
Net product revenue | $ | 2,351 | $ | 1,972 | 379 | 20 | % | |||||||||
Loss from operations | $ | (8,215 | ) | $ | (9,845 | ) | 1,630 | -17 | % | |||||||
Net loss attributable to common shareholders | $ | (9,226 | ) | $ | (12,202 | ) | 2,976 | -24 | % | |||||||
Net loss per share, basic and diluted | $ | (0.06 | ) | $ | (2.39 | ) | 2 | -97 | % | |||||||
Cost of Product Revenue: Total cost of product revenue increased by approximately
Research and Development: The R&D expense decreased by
Sales and Marketing: The Sales and Marketing expense decreased by approximately
General and Administrative: The G&A expense decreased by
Loss from Operations: Loss from operations decreased by
Net Loss: Net loss attributable to common shareholders decreased by approximately
Interest expense decreased by
Change in fair value of financial instrument and hybrid instrument designated at FVO increased by
Gain on extinguishment of debt increased by
Non-GAAP Recurring EBITDA: Non-GAAP recurring EBITDA for the first quarter of 2024 and the first quarter of 2023 were a net loss of
| Three Months Ending | ||||||||
| March 31, | ||||||||
(in thousands) | 2024 | 2023 | ||||||
| (unaudited) | ||||||||
Net loss attributable to common shareholders: | $ | (9,226 | ) | $ | (12,202 | ) | ||
Adjustments: | ||||||||
Interest expense | 611 | 2,181 | ||||||
Property and equipment depreciation | 17 | 20 | ||||||
Amortization of intangible assets | 484 | 484 | ||||||
Share-based compensation expense | 581 | 480 | ||||||
Income taxes | - | - | ||||||
Non-GAAP EBITDA | (7,533 | ) | (9,037 | ) | ||||
Non-GAAP Recurring EBITDA | $ | (7,533 | ) | $ | (9,037 | ) | ||
Note Regarding Use of Non-GAAP Measures
The Company supplements its condensed consolidated financial statements presented on a GAAP basis by providing non-GAAP EBITDA and non-GAAP recurring EBITDA, which are considered non-GAAP under applicable SEC rules. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects the basis upon which Company management assesses and operates the business. These non-GAAP financial measures are not in accordance with GAAP and should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes for, or superior to, measures of financial performance in conformity with GAAP.
The Company defines non-GAAP EBITDA as net loss before interest expense and other expense, depreciation of property and equipment, amortization of intangible assets, share-based compensation expense and provision for or benefit from income taxes. The Company defines non-GAAP Recurring EBITDA as non-GAAP EBITDA adjusted for certain non-recurring revenues and expenses. Company management believes that non-GAAP EBITDA and non-GAAP Recurring EBITDA are meaningful indicators of Jaguar's performance and provide useful information to investors regarding the Company's results of operations and financial condition.
Participation Instructions for Webcast
When: Tuesday, May 14, 2024, at 8:30 AM Eastern Time
Participant Registration & Access Link: Click Here
Replay Instructions for Webcast
Replay of the webcast on the investor relations section of Jaguar's website: (click here)
About Crofelemer
Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing innovative, patient-centric therapeutic solutions for essential supportive care and the management of neglected side effects across complicated disease states. Napo's goal is to redefine what is possible in supportive care, providing hope and improving outcomes for patients worldwide. Napo's crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit Jaguar on LinkedIn: https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/
About Mytesi®
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (
See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
About Gelclair®
INDICATIONS
GELCLAIR® has a mechanical action indicated for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including oral mucositis/stomatitis (may be caused by chemotherapy or radiation therapy), irritation due to oral surgery, traumatic ulcers caused by braces or ill-fitting dentures, or disease. Also, indicated for diffuse aphthous ulcers.
IMPORTANT SAFETY INFORMATION
Do not use GELCLAIR if there is a known or suspected hypersensitivity to any of its ingredients.
No adverse effects have been reported in clinical trials, although postmarketing reports have included infrequent complaints of burning sensation in the mouth.
If GELCLAIR is swallowed accidentally, no adverse effects are anticipated.
If no improvement is seen within 7 days, a physician should be consulted.
You are encouraged to report negative side effects of prescription medical products to the FDA.
Visit www.fda.gov/safety/medwatch, call 1-855-273-0468 or fill-in the form at this link.
Please see full Prescribing Information at: https://gelclair.com/assets/Gelclair_PI_Decemeber_2021.pdf
Important Safety Information About Canalevia®-CA1
For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
See full Prescribing Information at Canalevia.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that it will host an investor webcast May 14, 2024, the Company's expectation that results from the OnTarget study are imminent, the Company's expectation that it will begin the commercial launch in Q3 2024 for Gelclair, the Company's expectation that results from investigator-initiated and IND proof-of-concept studies of crofelemer for MVID and SBS with intestinal failure will be available in 2024, and the Company's expectation, that in accordance with the guidelines of specific EU countries, published data from clinical investigations of crofelemer in MVID and SBS could support early patient access to crofelemer for these conditions in those countries. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on accesswire.com
FAQ
What were Jaguar Health's revenues for Q1 2024?
How did Jaguar Health's Q1 2024 revenue compare to Q1 2023?
What is the significance of the Phase 3 OnTarget trial for Jaguar Health?
When is Jaguar Health planning to launch Gelclair?
How did Jaguar Health's net loss in Q1 2024 compare to Q1 2023?
What changes occurred in Jaguar Health's operational loss in Q1 2024?
How did Mytesi prescription volumes fare in Q1 2024?
What was the change in Jaguar Health's R&D expenses in Q1 2024?
Did Jaguar Health's cost of product revenue increase in Q1 2024?
